Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated over a 12-week double-blind period with extended follow-up reaching 15 months. The trial design is rigorous, including both an open-label extension and a randomized withdrawal phase to assess durability of effect. Results from this study will help clarify whether full-spectrum cannabis extracts can serve as a clinically viable alternative to existing pharmacologic options for chronic low back pain.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant adverse event profiles. The large sample size (820 participants) and double-blind design strengthen the reliability of efficacy and safety data, enabling clinicians to make evidence-based decisions about cannabis extracts as a potential alternative to opioids and other conventional analgesics. Successful demonstration of VER-01’s therapeutic benefit would expand the limited pharmacologic armamentarium for CLBP management and potentially reduce reliance on medications with greater abuse potential and systemic toxicity.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents meaningful evidence that a standardized full-spectrum cannabis extract may offer modest benefit for chronic low back pain, a condition where current pharmacologic options remain suboptimal. However, several clinical considerations warrant careful interpretation: the study’s reliance on a proprietary extract limits generalizability to other cannabis formulations available in practice, the magnitude of benefit should be quantified against placebo response rates which are often substantial in pain trials, and the long-term safety profile during the open-label extension requires full transparency regarding adverse events and dependency patterns. Additionally, whether this intervention would meaningfully improve function and quality of life compared to multimodal approaches combining physical therapy, behavioral strategies, and judicious use of conventional analgesics remains unclear from the abstract provided. For now, this evidence may support considering full-spectrum cannabis as an adjunctive option in selected patients with CLBP who have inadequate response to or intolerance of first-line therapies, though individual risk-benefit assessment and informed discussion about the current legal and